Evidence mapPaperPMID 41977428Full record

ArticleInternational journal of molecular sciences2026

Downregulation of the Transglutaminase 2-NF-κB Inflammatory Axis by a Fusion Protein of Cementoin and Secretory Leukocyte Protease Inhibitor Reduces Corneal Angiogenesis.

Juan Pablo Salica, María Constanza Potilinski, Gustavo Ortiz, Paulo C Maffia, Diego Guerrieri, Eduardo Chuluyan, Juan Eduardo Gallo

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Juan Pablo SalicaInstituto de Investigaciones en Medicina Traslacional (IIMT), Facultad de Ciencias Biomédicas, Universidad Austral, and CONICET, Pilar, Buenos Aires B1629, Argentina.ORCID 0000-0002-8735-8667
María Constanza PotilinskiInstituto de Investigaciones en Medicina Traslacional (IIMT), Facultad de Ciencias Biomédicas, Universidad Austral, and CONICET, Pilar, Buenos Aires B1629, Argentina.ORCID 0000-0003-4116-5875
Gustavo OrtizInstituto de Investigaciones en Medicina Traslacional (IIMT), Facultad de Ciencias Biomédicas, Universidad Austral, and CONICET, Pilar, Buenos Aires B1629, Argentina.
Paulo C MaffiaConsejo Nacional de Investigaciones Cientificas y Técnicas (CONICET), Buenos Aires C1425, Argentina.ORCID 0000-0001-7423-2646
Diego GuerrieriCentro de Estudios Farmacológicos y Botánicos (CEFYBO), Facultad de Medicina, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de Buenos Aires, Buenos Aires C1121, Argentina.
Eduardo ChuluyanCentro de Estudios Farmacológicos y Botánicos (CEFYBO), Facultad de Medicina, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de Buenos Aires, Buenos Aires C1121, Argentina.ORCID 0000-0003-3084-2500
Juan Eduardo GalloInstituto de Investigaciones en Medicina Traslacional (IIMT), Facultad de Ciencias Biomédicas, Universidad Austral, and CONICET, Pilar, Buenos Aires B1629, Argentina.ORCID 0000-0002-7502-6323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corneal alkali burns represent one of the most severe forms of ocular surface injury and frequently result in persistent inflammation, corneal neovascularization, stromal remodeling, and permanent visual impairment. Current therapeutic approaches incompletely control the inflammatory mechanisms that sustain pathological angiogenesis and tissue disorganization. In this study, we evaluated the effects of a transglutaminase-binding fusion protein (FP) in a rat model of alkali-induced corneal injury. Following standardized alkali burns, animals were treated topically with FP, secretory leukocyte protease inhibitor (SLPI), or Buffer. Corneal epithelial healing, opacity, and neovascularization were assessed clinically and by digital image-based quantification, while histological and immunofluorescence analyses were used to evaluate stromal organization and vascular invasion. Molecular mechanisms were investigated by RT-qPCR and Western blot analysis of key inflammatory, angiogenic, and signaling mediators. FP treatment significantly accelerated corneal re-epithelialization, reduced corneal opacity, and markedly attenuated corneal neovascularization compared to SLPI and Buffer controls. These effects were associated with coordinated downregulation of pro-inflammatory cytokines and angiogenic mediators, including TNF-α, IL-17, VEGF, and cPLA

Indexed as

Corneal NeovascularizationGTP-Binding ProteinsNF-kappa BRecombinant Fusion ProteinsSecretory Leukocyte Peptidase InhibitorTransglutaminasesAnimalsBurns, ChemicalCorneal InjuriesDown-RegulationMaleProtein Glutamine gamma Glutamyltransferase 2RatsRats, Sprague-DawleySignal TransductionGTP-Binding ProteinsNF-kappa BProtein Glutamine gamma Glutamyltransferase 2Recombinant Fusion ProteinsSecretory Leukocyte Peptidase InhibitorTgm2 protein, ratTransglutaminasesalkali injuryangiogenesiscementoincorneal inflammationcorneal neovascularizationcorneal wound healingNF-κBSLPITransglutaminase

Identifiers

PMID41977428
PMCPMC13073199

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.